Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use is generally not recommended in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary (excreted primarily via feces/bile).
* **Hepatic Impairment:** No dosage adjustment necessary.
## Contraindications
* Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis (use with caution).
* Type 1 diabetes or treatment of diabetic ketoacidosis (not indicated).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis (post-marketing reports), bullous pemphigoid, severe arthralgia, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy; consider alternative agent or monitor glycemic control closely if co-administration is necessary.
* **Insulin/Insulin Secretagogues (e.g., sulfonylureas):** Increased risk of hypoglycemia; dose reduction of the secretagogue may be required.
## Monitoring
* HbA1c (typically every 3–6 months).
* Blood glucose monitoring (especially when combined with insulin or sulfonylureas).
* Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **Hepatic Advantage:** Unlike other gliptins, linagliptin does not require renal adjustment, making it a convenient choice for patients with chronic kidney disease (CKD).
* **Administration:** May be taken with or without food.
* **Weight Neutrality:** Generally considered weight-neutral.
* **Dual Therapy:** Often combined with metformin; consider lowering the dose of sulfonylureas if initiated concurrently to mitigate hypoglycemia risk.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the latest manufacturer prescribing information (package insert) or local institutional guidelines before prescribing or administering medication, as clinical protocols may vary.
